Remove Development Remove Drug Trials Remove Medicine
article thumbnail

Small Pharma stock market launch funds DMT-based depression drug trial

pharmaphorum

UK-based Small Pharma has launched on the Toronto’s TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-dimethyltriptylene (DMT) to treat depression. The post Small Pharma stock market launch funds DMT-based depression drug trial appeared first on.

article thumbnail

Review reports improved transparency in antidepressant drug trials

Scienmag

New research suggests manufacturers of newly developed antidepressant drugs have become more forthcoming about clinical trials that don’t pan out.

Trials 83
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money. Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product.

article thumbnail

LSD biotech MindMed buys digital trial firm HealthMode

pharmaphorum

Psychedelic medicine biotech MindMed is to acquire digital medicine and therapeutics startup HealthMode for around $32.2 million, which uses artificial intelligence (AI) technology to speed up drug development. Karlin is also an Assistant Professor of Psychiatry at Tufts University School of Medicine.

Trials 134
article thumbnail

Lundbeck gets cold feet, axes schizophrenia drug trial

pharmaphorum

” Finding new medicines to treat schizophrenia has proved to be a tough task for Lundbeck – its share price cratered in late 2018 after another potential drug failed in a phase 3 trial. The post Lundbeck gets cold feet, axes schizophrenia drug trial appeared first on.

article thumbnail

Leading clinical packaging companies in contract marketing

Pharmaceutical Technology

Clinical packaging and labelling follow stringently controlled procedures and high-standard quality control measures to assure the safety and functionality of investigational medicinal products, during their storage, distribution, and use.

Packaging 100
article thumbnail

How does HTA for orphan drugs differ across Europe?

pharmaphorum

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always faced challenges when it comes to HTA approvals, even as governments bring in more regulatory policies that make their path through assessment easier. Rates of approval.

Drugs 122